Does the media refer more to IDXX or ISRG?

In the previous week, Intuitive Surgical had 39 more articles in the media than IDEXX Laboratories. MarketBeat recorded 42 mentions for Intuitive Surgical and 3 mentions for IDEXX Laboratories. Intuitive Surgical's average media sentiment score of 0.86 beat IDEXX Laboratories' score of 0.62 indicating that Intuitive Surgical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Intuitive Surgical 22 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor IDXX or ABT?

In the previous week, Abbott Laboratories had 29 more articles in the media than IDEXX Laboratories. MarketBeat recorded 32 mentions for Abbott Laboratories and 3 mentions for IDEXX Laboratories. Abbott Laboratories' average media sentiment score of 1.10 beat IDEXX Laboratories' score of 0.62 indicating that Abbott Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Abbott Laboratories 23 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer SYK or IDXX?

In the previous week, Stryker had 18 more articles in the media than IDEXX Laboratories. MarketBeat recorded 21 mentions for Stryker and 3 mentions for IDEXX Laboratories. Stryker's average media sentiment score of 1.07 beat IDEXX Laboratories' score of 0.62 indicating that Stryker is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stryker 16 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEXX Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IDXX or MDT?

In the previous week, Medtronic had 79 more articles in the media than IDEXX Laboratories. MarketBeat recorded 82 mentions for Medtronic and 3 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 0.62 beat Medtronic's score of 0.42 indicating that IDEXX Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Medtronic 28 Very Positive mention(s) 10 Positive mention(s) 14 Neutral mention(s) 14 Negative mention(s) 0 Very Negative mention(s) Neutral

IDEXX Laboratories (IDXX) Competitors

$562.16 -2.58 (-0.46%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$558.14 -4.01 (-0.71%)

As of 06/5/2026 07:21 PM Eastern

Compare

IDXX vs. NVST, ISRG, ABT, SYK, and MDT

Should you buy IDEXX Laboratories stock or one of its competitors? MarketBeat compares IDEXX Laboratories with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IDEXX Laboratories include Envista (NVST), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), Stryker (SYK), and Medtronic (MDT). These companies are all part of the "medical" sector.

How does IDEXX Laboratories compare to Envista?

IDEXX Laboratories (NASDAQ:IDXX) and Envista (NYSE:NVST) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, IDEXX Laboratories had 3 more articles in the media than Envista. MarketBeat recorded 3 mentions for IDEXX Laboratories and 0 mentions for Envista. IDEXX Laboratories' average media sentiment score of 0.62 beat Envista's score of 0.50 indicating that IDEXX Laboratories is being referred to more favorably in the media.

Company	Overall Sentiment
IDEXX Laboratories	Positive
Envista	Positive

IDEXX Laboratories has a net margin of 24.63% compared to Envista's net margin of 2.41%. IDEXX Laboratories' return on equity of 70.87% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	24.63%	70.87%	32.56%
Envista	2.41%	7.11%	3.91%

IDEXX Laboratories has higher revenue and earnings than Envista. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.45B	9.97	$1.06B	$13.58	41.40
Envista	$2.72B	1.38	$47M	$0.41	56.29

87.8% of IDEXX Laboratories shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by company insiders. Comparatively, 1.0% of Envista shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

IDEXX Laboratories currently has a consensus price target of $751.00, indicating a potential upside of 33.59%. Envista has a consensus price target of $28.83, indicating a potential upside of 24.94%. Given IDEXX Laboratories' stronger consensus rating and higher probable upside, equities research analysts clearly believe IDEXX Laboratories is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

IDEXX Laboratories has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Envista has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Summary

IDEXX Laboratories beats Envista on 14 of the 16 factors compared between the two stocks.

How does IDEXX Laboratories compare to Intuitive Surgical?

IDEXX Laboratories (NASDAQ:IDXX) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Intuitive Surgical has higher revenue and earnings than IDEXX Laboratories. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.45B	9.97	$1.06B	$13.58	41.40
Intuitive Surgical	$10.06B	14.85	$2.86B	$8.25	51.16

In the previous week, Intuitive Surgical had 39 more articles in the media than IDEXX Laboratories. MarketBeat recorded 42 mentions for Intuitive Surgical and 3 mentions for IDEXX Laboratories. Intuitive Surgical's average media sentiment score of 0.86 beat IDEXX Laboratories' score of 0.62 indicating that Intuitive Surgical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Intuitive Surgical	22 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive

IDEXX Laboratories presently has a consensus target price of $751.00, suggesting a potential upside of 33.59%. Intuitive Surgical has a consensus target price of $573.63, suggesting a potential upside of 35.91%. Given Intuitive Surgical's stronger consensus rating and higher probable upside, analysts clearly believe Intuitive Surgical is more favorable than IDEXX Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64
Intuitive Surgical	1 Sell rating(s)	7 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.67

Intuitive Surgical has a net margin of 28.15% compared to IDEXX Laboratories' net margin of 24.63%. IDEXX Laboratories' return on equity of 70.87% beat Intuitive Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	24.63%	70.87%	32.56%
Intuitive Surgical	28.15%	15.98%	14.07%

87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 83.6% of Intuitive Surgical shares are held by institutional investors. 0.8% of IDEXX Laboratories shares are held by insiders. Comparatively, 0.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

IDEXX Laboratories has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Intuitive Surgical has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Summary

Intuitive Surgical beats IDEXX Laboratories on 10 of the 16 factors compared between the two stocks.

How does IDEXX Laboratories compare to Abbott Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

IDEXX Laboratories has a net margin of 24.63% compared to Abbott Laboratories' net margin of 13.90%. IDEXX Laboratories' return on equity of 70.87% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	24.63%	70.87%	32.56%
Abbott Laboratories	13.90%	17.62%	10.01%

Abbott Laboratories has higher revenue and earnings than IDEXX Laboratories. Abbott Laboratories is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.45B	9.97	$1.06B	$13.58	41.40
Abbott Laboratories	$45.13B	3.52	$6.52B	$3.57	25.55

IDEXX Laboratories has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

IDEXX Laboratories currently has a consensus target price of $751.00, suggesting a potential upside of 33.59%. Abbott Laboratories has a consensus target price of $119.09, suggesting a potential upside of 30.58%. Given IDEXX Laboratories' higher probable upside, equities research analysts plainly believe IDEXX Laboratories is more favorable than Abbott Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

In the previous week, Abbott Laboratories had 29 more articles in the media than IDEXX Laboratories. MarketBeat recorded 32 mentions for Abbott Laboratories and 3 mentions for IDEXX Laboratories. Abbott Laboratories' average media sentiment score of 1.10 beat IDEXX Laboratories' score of 0.62 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Abbott Laboratories	23 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are held by institutional investors. 0.8% of IDEXX Laboratories shares are held by insiders. Comparatively, 0.5% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

IDEXX Laboratories beats Abbott Laboratories on 10 of the 17 factors compared between the two stocks.

How does IDEXX Laboratories compare to Stryker?

Stryker (NYSE:SYK) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

Stryker has higher revenue and earnings than IDEXX Laboratories. Stryker is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$25.12B	4.67	$3.25B	$8.64	35.38
IDEXX Laboratories	$4.45B	9.97	$1.06B	$13.58	41.40

IDEXX Laboratories has a net margin of 24.63% compared to Stryker's net margin of 13.20%. IDEXX Laboratories' return on equity of 70.87% beat Stryker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stryker	13.20%	23.42%	11.04%
IDEXX Laboratories	24.63%	70.87%	32.56%

Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Stryker presently has a consensus price target of $395.33, indicating a potential upside of 29.32%. IDEXX Laboratories has a consensus price target of $751.00, indicating a potential upside of 33.59%. Given IDEXX Laboratories' higher probable upside, analysts plainly believe IDEXX Laboratories is more favorable than Stryker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.73
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64

77.1% of Stryker shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 4.6% of Stryker shares are held by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Stryker had 18 more articles in the media than IDEXX Laboratories. MarketBeat recorded 21 mentions for Stryker and 3 mentions for IDEXX Laboratories. Stryker's average media sentiment score of 1.07 beat IDEXX Laboratories' score of 0.62 indicating that Stryker is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stryker	16 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEXX Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IDEXX Laboratories beats Stryker on 9 of the 16 factors compared between the two stocks.

How does IDEXX Laboratories compare to Medtronic?

IDEXX Laboratories (NASDAQ:IDXX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Medtronic has higher revenue and earnings than IDEXX Laboratories. Medtronic is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.45B	9.97	$1.06B	$13.58	41.40
Medtronic	$36.36B	2.88	$4.66B	$3.73	21.89

In the previous week, Medtronic had 79 more articles in the media than IDEXX Laboratories. MarketBeat recorded 82 mentions for Medtronic and 3 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 0.62 beat Medtronic's score of 0.42 indicating that IDEXX Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Medtronic	28 Very Positive mention(s)	10 Positive mention(s)	14 Neutral mention(s)	14 Negative mention(s)	0 Very Negative mention(s)	Neutral

87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.8% of IDEXX Laboratories shares are held by insiders. Comparatively, 0.3% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

IDEXX Laboratories presently has a consensus price target of $751.00, indicating a potential upside of 33.59%. Medtronic has a consensus price target of $99.00, indicating a potential upside of 21.23%. Given IDEXX Laboratories' stronger consensus rating and higher possible upside, equities analysts clearly believe IDEXX Laboratories is more favorable than Medtronic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64
Medtronic	0 Sell rating(s)	11 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.61

IDEXX Laboratories has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Medtronic has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

IDEXX Laboratories has a net margin of 24.63% compared to Medtronic's net margin of 13.20%. IDEXX Laboratories' return on equity of 70.87% beat Medtronic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	24.63%	70.87%	32.56%
Medtronic	13.20%	14.61%	7.80%

Summary

IDEXX Laboratories beats Medtronic on 12 of the 16 factors compared between the two stocks.

Get IDEXX Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IDXX vs. The Competition

Export

Metric	IDEXX Laboratories	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$44.55B	$7.20B	$6.47B	$12.42B
Dividend Yield	N/A	1.20%	2.68%	5.34%
P/E Ratio	41.40	45.87	23.82	23.63
Price / Sales	9.97	85.66	543.66	124.82
Price / Cash	37.43	24.88	42.42	57.17
Price / Book	27.97	6.95	9.73	6.35
Net Income	$1.06B	$159.22M	$3.57B	$337.59M
7 Day Performance	-0.24%	-2.59%	-1.25%	-2.51%
1 Month Performance	-2.95%	2.24%	0.83%	-0.69%
1 Year Performance	7.10%	-1.02%	24.11%	25.37%

IDEXX Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IDXX IDEXX Laboratories	3.7616 of 5 stars	$562.16 -0.5%	$751.00 +33.6%	+7.7%	$44.55B	$4.45B	41.40	11,000
NVST Envista	3.2365 of 5 stars	$23.34 -0.9%	$28.83 +23.5%	+23.5%	$3.83B	$2.72B	56.93	12,000
ISRG Intuitive Surgical	4.1552 of 5 stars	$412.26 -2.9%	$576.71 +39.9%	-24.4%	$150.39B	$10.06B	49.97	17,021	Analyst Forecast Insider Trade
ABT Abbott Laboratories	4.9576 of 5 stars	$87.70 +2.5%	$119.09 +35.8%	-31.8%	$149.10B	$44.33B	24.57	115,000	Positive News
SYK Stryker	4.9262 of 5 stars	$299.15 -1.9%	$395.48 +32.2%	-20.1%	$116.96B	$25.27B	34.62	56,000	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IDXX) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEXX Laboratories (IDXX) Competitors

IDXX vs. NVST, ISRG, ABT, SYK, and MDT

How does IDEXX Laboratories compare to Envista?

Summary

How does IDEXX Laboratories compare to Intuitive Surgical?

Summary

How does IDEXX Laboratories compare to Abbott Laboratories?

Summary

How does IDEXX Laboratories compare to Stryker?

Summary

How does IDEXX Laboratories compare to Medtronic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDXX vs. The Competition

IDEXX Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IDEXX Laboratories (IDXX) Competitors

IDXX vs. NVST, ISRG, ABT, SYK, and MDT

How does IDEXX Laboratories compare to Envista?

Does the media favor IDXX or NVST?

Is IDXX or NVST more profitable?

Which has better valuation and earnings, IDXX or NVST?

Do insiders & institutionals believe in IDXX or NVST?

Do analysts recommend IDXX or NVST?

Which has more risk and volatility, IDXX or NVST?

Summary

How does IDEXX Laboratories compare to Intuitive Surgical?

Which has higher valuation and earnings, IDXX or ISRG?

Does the media refer more to IDXX or ISRG?

Do analysts recommend IDXX or ISRG?

Is IDXX or ISRG more profitable?

Do insiders and institutionals hold more shares of IDXX or ISRG?

Which has more risk & volatility, IDXX or ISRG?

Summary

How does IDEXX Laboratories compare to Abbott Laboratories?

Is IDXX or ABT more profitable?

Which has higher earnings and valuation, IDXX or ABT?

Which has more risk and volatility, IDXX or ABT?

Do analysts prefer IDXX or ABT?

Does the media favor IDXX or ABT?

Do institutionals and insiders believe in IDXX or ABT?

Summary

How does IDEXX Laboratories compare to Stryker?

Which has preferable earnings and valuation, SYK or IDXX?

Is SYK or IDXX more profitable?

Which has more risk and volatility, SYK or IDXX?

Do analysts prefer SYK or IDXX?

Do institutionals and insiders believe in SYK or IDXX?

Does the media prefer SYK or IDXX?

Summary

How does IDEXX Laboratories compare to Medtronic?

Which has preferable earnings and valuation, IDXX or MDT?

Does the media refer more to IDXX or MDT?

Do institutionals & insiders believe in IDXX or MDT?

Do analysts prefer IDXX or MDT?

Which has more risk & volatility, IDXX or MDT?

Is IDXX or MDT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDXX vs. The Competition

IDEXX Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools